2Murata M, Shiraishi T. Cytochrome P4501A1 and glutathione S - transferase M1 genotypes as risk factors for prostate cancer in Japan. Jpn J Clin Oncol, 1998,28(11) :657 - 660.
3Tang YM, Green BL, Chen GF, et al. Human CYP1B1 Leu432Val gene polymerphism: ethnic distribution in African- Americans, Caucasians and Chinese;oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls. Pharmacogenetics, 2000,10( 9 ): 761 - 766.
4Fukatsu T, Hirokawa Y, Araki T, et al. Genetic polymorphisms of hormone -related genes and prostate cancer risk in the Japanese population. Anticancer Res,2004,24(4) :2431 - 2437.
5Mammen JS,Pittman GS,Li Y,et al. Single amino acid mutations,but not common polymoerphisms, decrease the activity of CYP1B1 against ( - )benzo[a]pyrene - 7R - trans - 7,8 - dihydrodiol. Carcinogenesis, 2003,24(7): 1247 - 1255.
6Sssaki M, Tanaka Y, Kaneuchi M, et al. CYP1B1 gene polymorphisms have higher risk for endometrial cancer, and positive correlations with estrogen receptor alpha and estrogen receptor beta expressions. Cancer Pes,2003,63(14) :3913 - 3918.
7Tanaka Y, Sasaki M, Kaneuchi M, et al. Polymorphisms of the CYP1B1 gene have higher risk for prostate cancer. Biochem Biophys Res Commun,2002,296(4) :820 - 826.
8Ntais C,Polycarpou A,Ioannidis JP.Association of the CYP17 gene polymorphism with the risk of prostate cancer: a meta- analysis. Cancer Epidemiol Biomarkers Prev,2003,12(2): 120 - 126.
9Wadelius M, Autrup JL, Stubbins MJ, et al. Polymorphisms in NAT2,CYP2D6,CYP2C19 and GSTP1 and their association with prostate cancer. Pharmacogenetics, 1999,9(3) :333 - 340.
10Ferreira PM, Medeiros R, Vasconcelos A, et al. Association between CYP2E1 polymorphisms and susceptibility to prostate cancer. Eur J Cancer Prev, 2003,12(3) :205 - 211.
